Clinical trials: Central Sensitization
Menopause, Healthy Female Participants
A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects
The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS.
- Trial name
- NCT07794150
- Testing
- Estradiol/Levonorgestrel Transdermal System
- Where
- 2 sites in United States, India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Osteoarthritis
A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain
The purpose of this study is to investigate which pain mechanisms that can be affected by etoricoxib compared to placebo (inactive medication)in subjects with painful knee osteoarthritis af 4 weeks of treatment.
- Trial name
- NCT01619150
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- C4Pain
Low Back Pain
Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients
The purpose of this study is to assess the benefits of Percutaneous Neuromodulation Therapy when compared to a reference sham treatment in the treatment of patients who have undergone surgical intervention for chronic low back…
- Trial name
- NCT00290238
- Testing
- Vertis Percutaneous Neuromodulation Therapy (PNT), Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- 8 sites in United States
- Volunteers
- 122 people
- Sponsor
- RS Medical
Tendinopathy
A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
- Trial name
- NCT03502434
- Testing
- SM04755, Vehicle, White Petrolatum
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Biosplice Therapeutics, Inc.
Smoking Cessation
Skin Sensitization Potential of a New Nicotine Patch
An investigation on the skin sensitization potential of a new nicotine patch. Evaluation of the potential of a new nicotine transdermal patch to cause sensitization in the skin after repeated applications.
- Trial name
- NCT00967070
- Testing
- Nicotine Patch
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- McNeil AB
Pain, Esophageal Sensitivity
Esophageal Hypersensitivity Study in Healthy Volunteers
The purpose of the study is to compare sensitivity and sensitization of visceral pain in the esophagus using different pain stimuli
- Trial name
- NCT00711048
- Testing
- AZD1386
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fibromyalgia
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
- Trial name
- NCT07637162
- Testing
- AXS-14 (esreboxetine)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Axsome Therapeutics, Inc.
Hyperalgesia
A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers
GSK189254 is a highly potent histamine 3 (H3) receptor antagonist which has demonstrated efficacy in the reduction of mechanical hyperalgesia and allodynia in the chronic constriction injury pre-clinical model of neuropathic pain…
- Trial name
- NCT00387413
- Testing
- Duloxetine, GSK189254
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fibromyalgia
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
- Trial name
- FORWARD (NCT07398417)
- Testing
- AXS-14 (Esreboxetine)
- Where
- 53 sites in United States
- Volunteers
- 620 people
- Sponsor
- Axsome Therapeutics, Inc.